Donidalorsen

Phase 3

Ionis Pharmaceuticals, Inc. (IONS)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

IONSPhase 3$7.2B

Donidalorsen Phase 3 Est. Readout

Donidalorsen• Hereditary Angioedema154

Dec 2026~Estimated

CT.gov

00%

Competitive Landscape

1 competitor in Hereditary Angioedema

View Full Landscape

Drug Information

Target Indication

Hereditary Angioedema

Clinical Trial

NCT04307381

Last updated: 12/29/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA1/19/2026

Dawnzera

Dawnzera is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

IONS

Ionis Pharmaceuticals, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

ION582Phase 3

Angelman Syndrome

OlezarsenPhase 3

Familial Chylomicronemia Syndrome

VolanesorsenPhase 3

Familial Chylomicronemia Syndrome

InotersenPhase 3

FAP

ION363Phase 3

Amyotrophic Lateral Sclerosis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts